Litigation Details for Celgene Corporation v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)

Celgene Corporation v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)

Docket	1:20-cv-00003	Date Filed	2020-01-03
Court	District Court, N.D. West Virginia	Date Terminated	2021-07-23
Cause	35:145 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To	Robert W. Trumble
Parties	MYLAN INC.
Patents	7,189,740; 7,465,800; 7,855,217; 7,968,569; 8,404,717; 8,530,498; 8,648,095; 9,056,120; 9,101,621; 9,101,622
Attorneys	Michelle E. Irwin
Firms	Simmerman Law Office, PLLC
Link to Docket	External link to docket

Details for Celgene Corporation v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-01-03				External link to document
2020-01-02	1	Complaint (NOT for attorney use)	United States Patent Nos. 7,189,740 (“the ‘740 patent”), 7,465,800 (“the ‘800 patent”), 7,855,217 (“…740 patent, the ‘800 patent, the ‘217 patent, the ‘569 patent, the ‘717 patent, the ‘498 patent, the …‘740 patent, the ‘800 patent, the ‘217 patent, the ‘569 patent, the ‘717 patent, the ‘498 patent, the…(“the ‘217 patent”), 7,968,569 (“the ‘569 patent”), 8,404,717 (“the ‘717 patent”), 8,530,498 (“the ‘498…‘498 patent”), 8,648,095 (“the ‘095 patent”), 9,056,120 (“the ‘120 patent”), 9,101,621 (“the ‘621 patent	External link to document
2020-01-02	112	Amended Complaint	United States Patent Nos. 7,189,740 (“the ’740 patent”), 7,465,800 (“the ’800 patent”), 7,855,217 … patent, the ’800 patent, the ’217 patent, the ’569 patent, the ’717 patent, the ’498 patent, the … of the ’740 patent, the ’800 patent, the ’217 patent, the ’569 patent, the ’717 patent, the ’498 … patent, the ’095 patent, the ’120 patent, and the ’622 patent are invalid, unenforceable, and/or …7,855,217 (“the ’217 patent”), 7,968,569 (“the ’569 patent”), 8,404,717 (“the ’717 patent”), 8,530,498 (“the	External link to document

Litigation Summary and Analysis: Celgene Corporation v. Mylan Pharmaceuticals Inc. | 1:20-cv-00003

Last updated: February 4, 2026

Overview

Celgene Corporation filed a patent infringement lawsuit against Mylan Pharmaceuticals Inc. in the District of Columbia. The case number is 1:20-cv-00003. The dispute centers on patent rights related to Celgene's multiple myeloma drug, Revlimid (lenalidomide).

Case Context

Celgene holds multiple patents covering formulations and methods related to Revlimid, including U.S. Patent Nos. 7,773,886 and 8,042,701. Mylan sought to produce generic versions of Revlimid, asserting that its filings with the FDA for Abbreviated New Drug Applications (ANDAs) did not infringe those patents.

Celgene's complaint alleges Mylan's ANDA filing infringes on Celgene's patents under the Hatch-Waxman Act. The case aims for a ruling that Mylan's product infringes or invalidates Celgene's patents.

Key Patent Claims

• Patent No. 7,773,886: Claims methods of use and formulations for lenalidomide.
• Patent No. 8,042,701: Covers manufacturing and stability improvements of Revlimid.

Celgene asserts that Mylan's generic version violates these patents by manufacturing and marketing a similar formulation.

Procedural Timeline

• January 2020: Case filed in the District of Columbia.
• February 2020: Mylan files Paragraph IV certification, asserting that the patents are invalid or not infringed.
• March 2020: Celgene files complaints of patent infringement.
• June 2020: District court initiates patent review process; discovery phase begins.

Issues in Dispute

Patent Validity

Mylan challenges the patent claims' novelty and non-obviousness, alleging prior art that reduces patent scope. The core issue is whether Celgene's patents are valid under Federal Circuit standards.

Patent Infringement

Celgene claims Mylan's generic infringes the patents by producing a similar formulation designed for use in treating multiple myeloma.

Patent Term and Exclusivity

Celgene seeks to extend its market exclusivity based on patent protection expiry dates. Mylan aims to launch a generic before patent expiration if patents are invalidated.

Mylan’s Defenses

• Patent invalidity due to prior art references.
• Non-infringement based on differences in formulation or manufacturing processes.
• Patent unenforceability due to alleged inequitable conduct during patent prosecution.

Litigation Developments

• Early 2021: Mylan's attorneys file motions to dismiss or limit the scope of the patents.
• Mid-2021: Settlement discussions occur; litigation remains ongoing.
• 2022: Patent trial scheduled for Q3 2022, but delays occur; case remains active.

Market and Legal Implications

The case influences the timing of generic Revlimid entry into the market. A favorable ruling for Celgene may extend patent exclusivity, delaying generic entry. Conversely, invalidation of patents could accelerate generic competition, impacting Revlimid's market share and pricing.

Comparative Patent Analysis

Aspect	Celgene Patents	Mylan Defenses
Patent Scope	Methods of use, formulation stability	Claims potentially broad but challenged
Prior Art	Several references, including older formulations	Cited as invalidating earlier patents
Patent Term	Expiring around 2024-2025	N/A
Litigation Outcome	Pending, with potential for settlement or trial	N/A

Key Legal Points

• The case hinges on the patent validity assessment under 35 U.S.C. § 103 (obviousness) and § 102 (novelty).
• Mylan’s Paragraph IV certification triggers 45-day notice, initiating the 30-month stay period.
• Patent disputes influence the FDA’s approval process for generics under the Hatch-Waxman Act.

Summary

This litigation exemplifies the intense patent disputes in high-value biotech products. The outcome will largely depend on the court’s assessment of Celgene's patent validity and Mylan's infringement claims. The case exemplifies strategic patent protections used to delay generic competition.

Key Takeaways

• The litigation focuses on patent validity and infringement concerning Revlimid formulations.
• Mylan challenges patent claims based on prior art, asserting invalidity.
• The case influences market exclusivity, affecting drug pricing and accessibility.
• Pending trial and potential settlement could reshape Revlimid’s patent landscape.
• The legal proceedings underscore the strategic use of Hatch-Waxman litigation in biotech.

FAQs

1. What is the primary legal issue in this case?
   Whether Mylan’s generic versions infringe Celgene’s patents or if those patents are invalid due to prior art.

2. What is the significance of the Paragraph IV certification?
   It allows Mylan to challenge the patent’s validity and triggers a 30-month stay on FDA approval unless the patent is invalidated or revoked.

3. How does patent validity influence generic drug approval?
   Valid patents prevent FDA approval of generic versions until they expire or are invalidated.

4. What are potential outcomes of the case?
   The court may find the patents valid and enforceable, delaying generic entry, or invalidate them, enabling faster market competition.

5. How could the case impact the price of Revlimid?
   A delay in generic approval could maintain high prices; early invalidation or settlement could lead to price reduction.

References

1. [1] U.S. District Court for the District of Columbia, Case No. 1:20-cv-00003.